Sex- and age-related changes in bone and serum osteocalcin

Vanderschueren, Dirk; Gevers, G; Raymaekers, G; Devos, Paul; Dequeker, Jan

doi:10.1007/bf02555041

Cited by 86 publications

(38 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results are supported by other studies, in which a corresponding increased level of BGP was found before the age of 30 years (25)(26)(27). Furthermore, we found a tendency towards increased fU Ca/Cr in the youngest group, consistent with earlier reports (25).…”

Section: Discussionsupporting

confidence: 95%

Insulin-like growth factors I and II in healthy women with and without established osteoporosis

Ravn

Overgaard

Spencer

et al. 1995

European Journal of Endocrinology

View full text Add to dashboard Cite

We measured serum concentrations of insulin-like growth factors I and II (IGF-I and IGF-II) by radioimmunoassay in 107 healthy women aged 28-78 years and in 116 women with established osteoporosis. The women with established osteoporosis were randomized to a 1-year double-blind, placebo-controlled treatment with continuous estrogen/progestogen, anabolic steroids, salmon calcitonin or placebo and the IGFs were measured every 6 months. Women less than 35 years of age had 29% higher levels of IGF-I (p < 0.001) as compared to women above that age. For women more than 35 years of age, we found no correlation between IGF-I and age (r = 0.02). Correspondingly, we found no significant changes in serum IGF-I in 10 women, who were followed with serial measurements of IGFs every 3 months from 2 years before to 1 year after menopause; IGF-II revealed no correlation with age (r = 0.04). In the group of 116 women with established osteoporosis, IGF-I was 30% lower (p < 0.01) as compared to a group of 19 height-, weight- and age-matched nonfractured women (mean age 64 years). The IGF-II levels were equal in the two groups. Over the 1-year therapeutic intervention period, an increase in IGF-I of 13-15% (p < 0.05) was seen in the nandrolone decanoate-treated group. The same tendency was seen for hormone replacement therapy, although it was not significant. In conclusion, the serum level of IGF-I is high in young women, when peak bone mass is attained, and low in postmenopausal women with established osteoporosis.

show abstract

Section: Discussionsupporting

confidence: 95%

Insulin-like growth factors I and II in healthy women with and without established osteoporosis

Ravn

Overgaard

Spencer

et al. 1995

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…The changes observed after OVX in this study are similar to the changes seen after the menopause in women. Increases in alkaline phosphatase activity, osteocalcin levels [26], and periosteal diameter, and a reduction in 24-hour Ca excretion and bone density are also observed in postmenopausal women [27]. The increased osteocalcin levels observed after OVX reflect a high turnover rate, as demonstrated earlier in ovariectomized dogs [28] and rats [29].…”

Section: Discussionmentioning

confidence: 85%

Mechanical properties, bone mineral content, and bone composition (collagen, osteocalcin, IGF-I) of the rat femur: Influence of ovariectomy and nandrolone decanoate (anabolic steroid) treatment

et al. 1993

Self Cite

View full text Add to dashboard Cite

Nandrolone decanoate (ND) is an anabolic steroid with a positive effect on bone mass in osteoporotic patients. The mechanism of action, (i.e., reduction of bone resorption and/or stimulation of bone formation), the ultimate effect on mechanical properties, and the most effective dosage are not yet clear. To address these issues, dose-related effects of the long-term effect of ND on serum and bone biochemistry, bone mineral content, and bone mechanical properties in ovariectomized (OVX) rats (12 weeks old at the start of the experiment) were studied for 6 months. The results were compared with those obtained in age-matched, intact, and OVX rats. OVX caused in the femur a significant increase in net periosteal bone formation and net endosteal bone resorption of bone collagen content and torsional strength, and of serum alkaline phosphatase, osteocalcin, and insulin-like growth factor-I (IGF-I) levels, whereas cortical bone density and calcium/creatinine and phosphorus/creatinine in 24-hour urine were significantly reduced. Treatment of OVX rats with 1 mg ND/14 days resulted in a significant increase in periosteal bone formation, femur length, cortical and trabecular bone mineral content and density, torsion stiffness and strength, and bone IGF-I content, and a decrease in serum osteocalcin, urinary calcium/creatinine levels, and bone collagen content compared with OVX controls. The higher ND dosage of 2.5 mg/14 days did not improve the results. ND treatment did not reverse all changes induced by OVS to the level of the intact controls. These results indicate that ND acts as an antiresorptive drug and as a home formation stimulating drug.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

“…Our results are in agreement with two published studies (33,34) but do not agree with four others. (35)(36)(37)(38) The reasons our correlations of bone markers with E 2 and P differ from those reported in other studies (4,8) are not entirely clear. Those studies did not report whether calculated correlations were from multiple data points per woman or whether they were within woman or between women.…”

Section: Figmentioning

confidence: 79%

Changes in Bone Resorption During the Menstrual Cycle

Chiu

Mayes³

et al. 1999

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

To determine if the cyclic changes of female sex hormones during the menstrual cycle are related to changes in bone formation and resorption, we measured serum bone-specific alkaline phosphatase (BAP) and osteocalcin (OC) and bone resorption markers, serum and urine deoxypyridinoline (Dpyr), three times per week during one menstrual cycle in 20 healthy premenopausal women. Serum estradiol (E 2 ) and progesterone (P) showed characteristic cyclic fluctuations. Serum Dpyr was higher during the follicular phase (

show abstract

Sex- and age-related changes in bone and serum osteocalcin

Cited by 86 publications

References 13 publications

Insulin-like growth factors I and II in healthy women with and without established osteoporosis

Insulin-like growth factors I and II in healthy women with and without established osteoporosis

Mechanical properties, bone mineral content, and bone composition (collagen, osteocalcin, IGF-I) of the rat femur: Influence of ovariectomy and nandrolone decanoate (anabolic steroid) treatment

Changes in Bone Resorption During the Menstrual Cycle

Contact Info

Product

Resources

About